BCL2 and breast carcinoma: MAPK3 (ERK1) was upregulated after the first parabola and is interacting with RELA, CASP3 and BCL2. It is known that NF-κB inhibits ERK activation to enhance cell survival during the development of tumor adaptive radioresistance in breast cancer cells [74].